



ASX Release Tuesday, 24 January 2006

BresaGen commences 2006 with additional Contracts for new & existing clients

Adelaide biotechnology Company, BresaGen Limited, has executed contracts worth \$680,000 in January 2006 with Caldeon Pty Ltd and Tissue Therapies Ltd.

BresaGen now provides several Australian biotech companies with process development and supply of material for various stages of product development. These include, CBio, Hunter Immunology, Caldeon, Tissue Therapies, QRx, Imugene and Psiron.

"At Tissue Therapies we are very happy to have established a commercial relationship with BresaGen," said Dr Steven Mercer, CEO of Tissue Therapies. "Not only because of the ease of working with an Australian company, but also because BresaGen's scientific staff have well deserved international respect and world-class technical capabilities." He added "we've been impressed with the excellent results achieved with various research projects they've conducted for us over the last 14 months, which gives us great confidence that they will meet our requirements for clinical trial material."

The process of conducting initial feasibility studies, with the product eventually transitioning into full GMP production, is a core strategy for BresaGen, and is an illustration of the company's ability and capacity to work successfully across the process development spectrum.

About BresaGen Limited (BGN)

BresaGen is a biotechnology company focussed on cost-effective production of proteins and peptides in bacteria. The Company is located in Adelaide, South Australia and specialises in process development and supply of clinical trial material for third parties through its protEcol™ Services business unit. The Company focus is on supply of protein-based active pharmaceutical ingredients (API's) to pharmaceutical and biotechnology companies.

www.bresagen.com.au

Postal Address 8 Dalglish Street
PO Box 259 Thebarton SA 5031
Rundle Mall SA 5000 Australia www.bresagen.com.au

Telephone +61 8 8234 2660
Facsimile +61 8 8234 6268
Email adelaide@bresagen.com.au

BresaGen Limited
ACN 007 988 767
ABN 60 007 988 767